Oruka Therapeutics, Inc. quarterly report, Q3 FY2021

Filing identity and reporting period

Important discrepancy: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q for the quarter ended September 30, 2021, not a filing for Oruka Therapeutics, Inc. The summary below reflects the filing text provided.

ARCA is a clinical-stage biopharmaceutical company with no product revenue. Its lead candidates are rNAPc2 (AB201), under study for hospitalized COVID-19 patients, and Gencaro, being developed for atrial fibrillation in patients with heart failure.

Financial results and liquidity

Amounts below are in millions of dollars unless noted.

Because ARCA had no revenue, profit margins are not applicable. At September 30, 2021, cash and cash equivalents were $58.313 million, current assets were $59.666 million, current liabilities were $3.182 million, total liabilities were $3.592 million, and stockholders’ equity was $56.600 million. The company reported operating lease liabilities; the filing reports no material borrowing balance. Cash increased $9.242 million during the first nine months, reflecting $23.093 million of net financing cash inflow, principally from common-stock sales, offset by operating and investing cash use.

Changes versus comparable periods

• Q3 R&D expense rose $2.387 million year over year; nine-month R&D expense rose $8.103 million, primarily due to rNAPc2 clinical-trial and manufacturing-development activity.
• Q3 G&A expense increased $0.339 million and nine-month G&A increased $0.912 million, mainly from personnel and insurance costs.
• Nine-month net loss increased from $4.613 million to $13.646 million, while operating cash use increased from $4.730 million to $13.815 million.
• Cash was higher than at December 31, 2020, but the company raised $23.1 million net through stock issuance during the nine-month period. Shares outstanding increased from 9,548,150 at year-end 2020 to 14,410,143 at September 30, 2021.

Outlook, developments, and risks

• Management estimated that September 30 cash would fund operations through the end of fiscal 2022. A Phase 3 rNAPc2 trial or the Gencaro PRECISION-AF Phase 3 trial would likely require additional financing. Management cautioned that actual cash use could differ from its estimates.
• ARCA was enrolling patients in its international Phase 2b ASPEN-COVID-19 trial. In July 2021, it increased planned enrollment from 100 to 160. In October 2021, the data and safety monitoring committee recommended completing the trial without changing its design; management anticipated topline results in Q1 2022. These were expectations, not reported results.
• PRECISION-AF remained on hold, pending additional financing and improvement in the pandemic sufficient to support patient recruitment. The filing describes Gencaro’s Phase 3 program as requiring substantial additional capital.
• In July 2021, ARCA obtained exclusive worldwide patent rights related to rNAPc2 from the University Medical Center Mainz. Potential upfront and milestone obligations could total approximately €1.6 million, plus low-single-digit royalties if the product is approved and commercialized.
• ARCA had up to $50 million available under its amended at-the-market equity offering prospectus. Further equity financing could materially dilute shareholders; financing or strategic transactions might not be available on acceptable terms.
• Key risks include clinical-trial efficacy, safety and enrollment; regulatory approval; competition and changing COVID-19 treatment needs; reliance on third-party manufacturers and research organizations; intellectual-property protection; Nasdaq listing compliance; and the company’s ability to secure funding. The filing says the statements use a going-concern basis while warning that future funding uncertainty could affect continued operations.
• The filing reports no legal proceedings and states that disclosure controls were effective at a reasonable level of assurance, with no material quarterly change in internal control over financial reporting.

Most important facts for investors to verify

1. Confirm the issuer: the supplied document identifies ARCA biopharma, Inc., not Oruka Therapeutics, Inc.
2. Check subsequent ASPEN-COVID-19 trial results and whether a Phase 3 program was initiated, funded, or altered.
3. Verify cash runway against actual operating cash burn, financing activity, and any later liquidity disclosures.
4. Review the timing, funding, and status of PRECISION-AF and any Gencaro development plans.
5. Assess dilution from additional equity issuance and the terms or availability of strategic financing.
6. Confirm the status and financial terms of the Mainz patent agreement, including any payments or royalty obligations.